Flynn James E Insider Trading Activity (NUVL)

Summary

Updated Jul 16, 2026

Flynn James E has filed 3 SEC Form 4 filings across 3 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $55.00M. Lifetime open-market sales: $219.31M. Historical track record: 1/5 stars across 7 tracked purchases.

Profile

James E. Flynn is a corporate insider known for his roles in various biopharmaceutical companies, including Nuvalent, Inc. and Larimar Therapeutics, Inc. He has held positions as a director and significant owner in these firms, contributing to their strategic direction.

Role	Director, 10% Owner
Notability	30/100

Board memberships

Nuvalent, Inc.
Larimar Therapeutics, Inc.
BiomX Inc.
ARS Pharmaceuticals, Inc.

Awards & honors

Director at multiple biopharmaceutical companies
Significant ownership stake in Nuvalent, Inc.

Track Record

InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.

InsiderAlpha rating	★☆☆☆☆ (1/5)
Total purchases tracked	7
Purchases with forward-return data	7
30-day win rate	4286%
90-day win rate	4286%
Avg 5-day return	+497.48%
Avg 30-day return	-766.48%
Avg 90-day return	-905.72%
Best 30-day return	+722.54%

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-06-18	NUVL	Nuvalent, Inc.	A — Grant or award	3.4K	$0.00
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	407.1K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	407.1K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	261.0K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	261.0K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	149.2K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	149.2K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	123.0K	—
2026-06-12	PBLS	Parabilis Medicines, Inc.	J — Other acquisition / disposition	123.0K	—
2026-03-03	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	2.00M	$5.00	$10.00M
2026-03-03	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	832.0K	$5.00	$4.16M
2026-03-03	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	1.08M	$5.00	$5.42M
2026-03-03	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	1.08M	$5.00	$5.42M
2025-07-31	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	2.60M	$3.20	$8.32M
2025-07-31	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	3.39M	$3.20	$10.84M
2025-07-31	LRMR	Larimar Therapeutics, Inc.	P — Open-market purchase	3.39M	$3.20	$10.84M
2025-06-27	SPRY	ARS Pharmaceuticals, Inc.	S — Open-market sale	370.1K	$18.46	$6.83M
2025-06-27	SPRY	ARS Pharmaceuticals, Inc.	S — Open-market sale	370.1K	$18.46	$6.83M
2025-06-18	NUVL	Nuvalent, Inc.	A — Grant or award	2.6K	$0.00
2025-06-18	NUVL	Nuvalent, Inc.	A — Grant or award	2.6K	$0.00

Frequently Asked Questions

Who is Flynn James E?

How many SEC Form 4 filings has Flynn James E submitted recently?

3 primary Form 4 filings in the last 90 days, covering 3 companies.

Has Flynn James E been buying or selling stock?

Recorded transactions: 7 open-market purchases ($55.00M) and 12 open-market sales ($219.31M) across all tracked filings.

How accurate is Flynn James E's historical track record?

Across 7 tracked purchases, Flynn James E averaged -766.5% avg 30-day return with a 4286% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.

Where can I see all of Flynn James E's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Flynn James E — SEC Form 4 Insider Trading Activity